Abbott India Q1 FY27 Results (NSE: ABBOTINDIA)
Signal: Steady quarter
The read
The key inflection is earnings conversion: revenue grew only 4.3% YoY to ₹1813.68 Cr, while EBITDA rose 15.3% to ₹597.87 Cr and PAT increased 17.1% to ₹428.52 Cr; however, the filing does not disclose the cost or mix driver behind the outperformance.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹1,813.68 Cr | 4.3% | N/A |
| EBIT | ₹578.12 Cr | 15.9% | |
| Net profit | ₹428.52 Cr | 17.1% | |
| EPS | ₹201.66 | 17.1% | |
| EBIT margin | 33% |
P&L walk
Standalone revenue grew 4.3% YoY to ₹1813.68 Cr, but EBITDA rose 15.3% to ₹597.87 Cr and PAT increased 17.1% to ₹428.52 Cr, showing earnings growth materially ahead of sales; sequential trends were not disclosed.
Key positives
- EBITDA of ₹597.87 Cr grew 15.3% YoY versus revenue growth of 4.3%, demonstrating stronger earnings conversion than topline growth.
- PAT rose 17.1% YoY to ₹428.52 Cr and EPS rose 17.1% YoY to ₹201.66, with EPS tracking PAT and no dilution signal.
- EBIT of ₹578.12 Cr increased 15.9% YoY, confirming that profit growth was primarily supported by operating performance rather than a reported exceptional item.
Key concerns
- Revenue growth was limited to 4.3% YoY at ₹1813.68 Cr, and the filing does not disclose product, geography, volume or price/mix drivers to assess the durability of topline momentum.
- The filing does not provide prior-period EBITDA margin, raw-material costs, R&D expenditure or product/geography splits, limiting diagnosis of the 15.3% EBITDA growth.
Research and educational content only. Not investment advice.